- Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data💸 A Series A extension: US-China biotech Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform. The San Diego and Shanghai biotech has raised $95 mil…Endpoints · 2mo ago↗ source
- <![CDATA[REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer]]><![CDATA[Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.]]>onclive · 2mo ago↗ source
- AstraZeneca follows Merck with Phase 3 win in bladder cancerA combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek ap…